A New Delivery Engine
for Solid Tumor Oncology
KOP's proprietary TGM platform pairs a tumor-seeking peptide carrier with antisense oligonucleotide (ASO) payloads — achieving intracellular mRNA knockdown of oncogenes that have historically been undruggable, in solid tumors beyond the liver.
TGM
Platform Name
Targeted Genomic Messenger
ASO
Payload Class
Antisense oligonucleotide
Extra-hepatic
Delivery Profile
Solid tumor targeting
Modular
Architecture
Swap ASO for new targets
Three-Step Mechanism of Action
The TGM platform operates through a precise sequence: targeted delivery, cellular uptake, and oncogene silencing.
Target — Tumor-Selective Peptide Finds the Cell
A tumor-selective peptide carrier binds receptors overexpressed on cancer cells. Primary address: V1/VC1 peptide — demonstrated in vitro across breast and prostate tumor types with selectivity over low-receptor controls, backed by human clinical imaging precedent. Second address: IR peptide — a breast-selective targeting peptide with direct evidence of peptide-mediated ASO cargo uptake.
Deliver — Multivalent Scaffold Carries the Payload In
A cleavable conjugate carries the ASO payload into the cell. The platform deploys a tunable multivalent scaffold engineered to reward receptor binding with cytosolic payload release. Productive internalization and endosomal escape are measured directly by a head-to-head assay with strict go/no-go criteria — in collaboration with Galenvs Sciences.
Silence — ASO Knocks Down the Oncogenic Driver
The ASO payload hybridizes to the target oncogene mRNA — CCND1 (cyclin D1), BIRC5 (survivin), or other hard-to-drug drivers — triggering RNase H-mediated degradation. Up to 95% knockdown achieved in preclinical models. The modular architecture means both the targeting ligand and the payload are interchangeable: a platform, not a single molecule.
KOP Targeted Cancer Cell Therapy — Platform Pipeline Overview
A Modular Oncology Delivery Platform — In Vivo by Q1 2027
KOP's TGM platform is a receptor-targeted peptide-ASO conjugate system: a defined chemical entity pairing a tumor-selective targeting peptide with a gene-silencing ASO payload through a cleavable linker. Both the targeting ligand and the payload are interchangeable — a platform, not a single molecule. The platform has established tumor-selective targeting, peptide-mediated cargo uptake, and validated payload potency. The next milestone: one to two in vivo-ready conjugates into PK/PD studies by Q1 2027, in collaboration with Galenvs Sciences.
Targeted Delivery — Two Receptor Addresses
Primary: V1/VC1 peptide with in vitro proof across breast and prostate. Second: IR peptide with direct evidence of peptide-mediated ASO cargo uptake in breast cancer cells
Multivalent Scaffold — Engineered for Internalization
Tunable valency scaffold deploys multivalency behind the receptor that rewards it, with cytosolic payload release. Endosomal escape measured by head-to-head assay with strict go/no-go criteria
Optimized Payloads — Up to 95% Knockdown
ASO leads finalized with conjugate design complete. CCND1 and BIRC5 targets validated. Lead candidate selection converging on 1–2 in vivo-ready conjugates for PK/PD studies
ONCOGENE KNOCKDOWN — PRECLINICAL RESULTS
In vitro: 24-hr screen, mean across 3 cancer cell lines. In vivo: Charles River PC3 xenograft.
Why Existing Platforms Fall Short
Current RNA delivery technologies are constrained by liver-first biodistribution and systemic toxicity. KOP's TGM platform is engineered specifically for solid tumors.
| Platform | Delivery Route | Solid Tumor Access | Toxicity Profile | Modular Targets |
|---|---|---|---|---|
| GalNAc Conjugates | Hepatocyte-selective | ✕ Liver only | Low (hepatic) | ✕ Limited |
| LNP / Lipid Nanoparticles | Systemic IV | ⚠ Poor | Inflammatory / immunogenic | ⚠ Complex |
| Naked ASO | Systemic | ⚠ Limited | Off-target effects | ✓ Yes |
| KOP TGM Platform | Receptor-targeted | ✓ Extra-hepatic | No observed (preclinical) | ✓ Yes |
From Lead Optimization to In Vivo — Q1 2027
A single forward path: optimize, select, and advance the lead conjugate into in vivo PK/PD studies. In collaboration with Galenvs Sciences.
Lead & Construct Optimization
Finalize ASO leads and conjugate design
Delivery & Valency Selection
Head-to-head uptake assay to pick receptor address + valency
Candidate Selection
Converge on 1–2 in vivo-ready conjugates
In Vivo PK/PD Studies
Advance lead candidate(s) into animal PK/PD studies
Milestone: One to two in vivo-ready conjugates into PK/PD studies by Q1 2027 — Galenvs Sciences collaboration
Modular Architecture Enables Rapid Target Expansion
By swapping the ASO payload while retaining the peptide delivery vehicle, KOP can address new oncogene targets and tumor types without redesigning the platform.
Prostate Cancer
Target: CCND1 / BIRC5
Breast Cancer
Target: CCND1
Brain Cancer (GBM)
Target: CCND1
Ovarian Cancer
Target: CCND1
A De-Risked, Mechanism-Led Delivery Platform
Established tumor-selective targeting, validated payload potency, and an engineered multivalent scaffold. One to two in vivo-ready conjugates into PK/PD studies by Q1 2027.